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Local Recurrence of Hepatocellular
Carcinoma after Segmental Transarterial
Chemoembolization: Risk Estimates
Based on Multiple Prognostic Factors
Objective: To determine the prognostic factors for local recurrence of nodular
hepatocellular carcinoma after segmental transarterial chemoembolization. 
Materials and Methods: Seventy-four nodular hepatocellular carcinoma
tumors  5 cm were retrospectively analyzed for local recurrence after segmen-
tal transarterial chemoembolization using follow-up CT images (median follow-up
of 17 months, 4 77 months in range). The tumors were divided into four groups
(IA, IB, IIA, and IIB) according to whether the one-month follow-up CT imaging,
after segmental transarterial chemoembolization, showed homogeneous (Group
I) or inhomogeneous (Group II) iodized oil accumulation, or whether the tumors
were located within the liver segment (Group A) or in a segmental border zone
(Group B). Comparison of tumor characteristics between Group IA and the other
three groups was performed using the chi-square test. Local recurrence rates
were compared among the groups using the Kaplan-Meier estimation and log
rank test.
Results: Local tumor recurrence occurred in 19 hepatocellular carcinoma
tumors (25.7%). There were: 28, 18, 17, and 11 tumors in Group IA, IB, IIA, and
IIB, respectively. One of 28 (3.6%) tumors in Group IA, and 18 of 46 (39.1%)
tumors in the other three groups showed local recurrence. Comparisons between
Group IA and the other three groups showed that the tumor characteristics were
similar. One-, two-, and three-year estimated local recurrence rates in Group IA
were 0%, 11.1%, and 11.1%, respectively. The difference between Group IA and
the other three groups was statistically significant (p = 0.000).
Conclusion: An acceptably low rate of local recurrence was observed for small
or intermediate nodular tumors located within the liver segment with homoge-
neous iodized oil accumulation. 
urgical resection or transplantation has been considered as the gold
standard for treatment of hepatocellular carcinoma (HCC) in patients
who are surgical candidates (1, 2). However, the surgical indications are
usually very limited; consequently transcatheter arterial chemoembolization (TACE)
has been widely implemented for the treatment of patients with unresectable HCC
(3 8). The prognostic factors for local recurrence of HCC tumors, after segmental
TACE, are already well known and include tumor size and homogeneity of iodized oil
accumulation (9, 10). However, we recently reported that the tumor location in the
segmental border zone was also an important prognostic factor of local tumor
recurrence after TACE (11). We found that tumors located in the segmental border
zone showed a higher incidence of local recurrence compared to other tumors (11).
In this study, we evaluated the local tumor recurrence rate of HCC, after segmental
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STACE, by classifying the tumors based on multiple
prognostic factors. We also attempted to determine
whether a group with clinically favorable outcome could
be identified. In addition, we provide practical guidelines
for choice of interventional treatment modality in patients
with nodular small or intermediate sized tumors. 
MATERIALS AND METHODS
Patient Selection
Requirements for study participation were as follows: (a)
an adult patient with hepatic cirrhosis and either a single 5
cm in diameter HCC or smaller, or as many as three 3 cm
each in diameter or smaller HCCs, (b) absence of vascular
invasion or extrahepatic metastases, (c) sharp definition
from the surrounding liver parenchyma without evidence of
adjacent satellite nodules, (d) hepatic cirrhosis classified as
Child-Pugh class A or B, (e) prothrombin time ratio (i.e.,
normal time divided by patient’s time) greater than 40%,
(f) platelet count higher than 40,000 per cubic millimeter
(40 10
9 /L), (g) no previous treatment for HCC, (h) ineligi-
bility for surgical resection or transplantation, (i) patient
agreement to have TACE, (j) no residual enhanced area
within or around the tumors on the one-month follow-up
CT imaging. The reason for the confined inclusion criteria
to nodular small or intermediate tumors was to facilitate
comparison with the clinical results from other treatment
modalities such as radiofrequency (RF) ablation. From July
1998 to November 2005, 372 patients with HCC had been
referred to our center for TACE. Among them, 74 tumors
in 59 patients were included in our study. The median
follow-up period was 17 months (4 77 months). All but
two patients were male. Their age ranged from 44 to 78
years (mean SD: 62.5 9.5 years). The tumor size ranged
from 1.0 cm to 4.5 cm (mean SD: 2.4 0.9 cm).
Additional patient characteristics are shown in Table 1. 
For nine patients, the diagnosis of HCC was proved
histopathologically. For the other patients, the diagnosis
was established on the basis of characteristic imaging
findings on the three-phase helical computed tomography
(CT) and conventional angiography and/or the presence of
elevated tumor marker levels in serum (alpha-fetoprotein
level > 200 ng/mL) (12). In the vast majority of patients,
the etiology of cirrhosis was chronic viral hepatitis B or C
(Table 1).
Chemoembolization Techniques 
All patients had enhanced dynamic CT within four
weeks prior to TACE. All the TACE procedures were
performed by interventional radiologists with experience
of over five and three years. Hepatic angiography was
performed using 5-Fr angiographic catheters, followed by
superselection of segmental arterial feeders using a
microcatheter. Then we administered an iodized oil-
doxorubicin hydrochloride (Adriamycin; Kyowa Hakko
Kogyo, Tokyo, Japan) emulsion into the feeders. The
volume of iodized oil ranged from 3 to 10 ml, and the
amount of doxorubin ranged from 20 to 70 mg. Once the
flow became sluggish, gelatin sponge particles (Gelfoam;
Upjohn, Kalamazoo, MI) that were mixed with mitomycin-
C (Kyowa Hakko Kogyo, Tokyo, Japan) and contrast
material (Iopromide; Schering, Berlin, Germany) were
administered into the feeders until blood flow stopped
completely. While performing the segmental TACE,
attempts were made to completely occlude the arterial
feeder. A small amount of saline solution was then injected
slowly to confirm the complete occlusion of the segmental
arterial feeder. If contrast media retention was partially
washed out after the saline injection, additional gelatin
sponge particles were infused until complete stasis of flow
was obtained. 
Among the 74 tumors, three were supplied by both
segmental arteries on selective angiography using
microcatheters. In these circumstances, both segmental
feeding arteries were embolized. 
Analysis of Risk Factors for Local Tumor Recurrence
and CT Interpretation
Local recurrence rate was compared by 12 possible
prognostic factors: patient age, hepatitis C infection,
modified Child-Pugh classification, number of tumors, size
of tumor nodule, serum alpha-fetoprotein level, serum
albumin level, platelet count, homogeneity of iodized oil
accumulation within the nodule, tumor location in segmen-
tal border zone, tumor location in subcapsular area, and
contact of tumor with adjacent vessels. 
The number of tumors was determined by pre-emboliza-
tion CT. Tumor size was determined as the maximal
diameter of the nodule measured on the pre-embolization
CT. The CT examinations were performed with an 8-slice
multidetector CT scanner (Lightspeed; GE Medical
Systems, Milwaukee, WI) with 5-mm collimation and 17.5-
mm/sec table speed, or a single-detector helical scanner
(Prospeed Advantage; GE Medical Systems, Milwaukee,
WI) with 10-mm collimation and a 10-mm/sec table speed.
The border zone between hepatic segments was
determined by tracing the portal venous tree during the
portal phase of the spiral CT scan (13, 14). The segmental
border zone was defined as an area without traceable
portal veins between hepatic segments on the CT scan.
Segmental border zone lesions were defined as lesions
crossing an imaginary border between hepatic segments.
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enhanced three-phase helical CT four weeks after the
TACE. The pattern of iodized oil accumulation in the
masses was evaluated with the four-week follow-up CT
scan. When the tumor nodules showed compact iodized-oil
accumulation without any defect, they were classified as a
“homogeneous” pattern; otherwise they were classified as
an “inhomogenous” pattern. 
When the tumor nodules showed sharp definition from
the surrounding liver parenchyma, without evidence of
adjacent satellite nodules, they were classified as
“nodular” tumors. Otherwise, they were classified
“nonnodular” tumors.
Tumor location was classified as either subcapsular
(abutting the hepatic capsule) or nonsubcapsular. The
tumors were also classified into two groups of contacting
or non-contacting tumors according to their position
relative to adjacent visible (> 1-mm diameter) blood
vessels on the basis of whether part of the tumor was
attached to the vessel or not (15). These two factors were
known as potential predictors of local recurrence after RF
ablation (15 18).
Residual viable tumor was determined to be present
when an enhanced portion was observed within or around
the original mass on the one-month follow-up CT scan. If
no definite evidence of residual tumor was noted on this
one-month follow-up CT, then a three-phase contrast-
enhanced CT was performed at 3- or 4-month intervals
thereafter. Local tumor recurrence was determined to be
present when iodized oil from the lesion disappeared, or
when an enhanced portion was seen within or at the
margin of the original mass on the next follow-up CT scan,
after the first one-month follow-up CT scan. For recurrent
tumors, additional therapies such as TACE or RF ablation
were performed.
Two abdominal radiologists with five and four years of
experience interpreted the CT images including segmental
zonal anatomy independently; they were blinded to
whether the tumor showed local recurrence on the follow-
up CT images. Final decisions were reached by consensus. 
Statistical Analysis 
For the 12 potential prognostic factors of local tumor
recurrence, univariate and multivariate analyses were
performed using the Cox proportional hazard model.
Parameters that proved to be significant with the univari-
ate analysis were subsequently tested with the multivariate
Cox proportional hazard model.
Specifically, nodular tumors were divided into four
groups as IA, IB, IIA, or IIB according to whether they
showed homogeneous (Group I) or inhomogeneous (Group
II) iodized oil accumulation on the one-month follow-up
CT imaging, after segmental TACE, or whether they were
located within the liver segment (Group A) or within the
segmental border zone (Group B). 
Tumor characteristics such as tumor size, iodized oil
uptake pattern on the one-month follow-up CT imaging as
well as laboratory data were compared between Group IA
and the other three groups combined as well as between
each group. Comparison of tumor characteristics and
laboratory data between the groups was performed using
the chi-square test. The local recurrence rate was
compared between the groups using the Kaplan-Meier
method and the log rank test. 
P-values less than 0.05 were considered statistically
significant. The SPSS software package (Version 10.0;
SPSS Inc., Chicago, IL) was used for statistical analysis. 
RESULTS
The median CT follow-up was 17 months, with a range
of 4 78 months. Local tumor recurrence occurred in 19 of
the 74 nodular HCC tumors (25.7%). Among the 12
possible prognostic factors, the iodized oil uptake pattern
within the tumor and the tumor location in the segmental
border zone were statistically significant adverse prognos-
tic factors (c = 0.001 and 0.010, respectively). However,
other factors such as tumor size, patient age, modified
Child-Pugh classification, hepatitis C, or serum alpha-
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Table 1. Patient and Tumor Characteristics
Characteristics Number %
Age (yrs)
< 60 29 52.5
60 30 47.5
Underlying causes
Hepatitis B 39 72.5
Hepatitis C 13 15.0
Others 07 12.5
Modified Child-Pugh class
A 42 75.0
B 17 25.0
Serum alpha-fetoprotein level
40 ng/ mL 33 62.5
40 400 ng/ mL 22 30.0
> 400 ng/ mL 04 7.5
Number of tumors
Single 40 60.0
Double 14 27.5
Triple 05 12.5
Tumor maximal diameter (cm)
3 46 72.5
3 5 13 27.5fetoprotein level, serum albumin level, platelet count,
tumor location in the subcapsular area, or contact of tumor
with adjacent hepatic vessels were not significantly associ-
ated with local tumor recurrence (Table 2). Of note was
that the tumor location in the subcapsular area and contact
of the tumor with adjacent hepatic vessels were not associ-
ated with local recurrence (Table 2). The local recurrence
rate of intermediate tumors after segmental TACE (4/17;
23.5%) was similar to that of small HCC (15/57; 26.3%).
Multivariate analysis revealed that the iodized oil uptake
pattern within the tumor and the tumor location within the
segmental border zone were statistically significant
independent prognostic factors (p = 0.000 and 0.004,
respectively). 
There were 28, 18, 17 and 11 tumors in Group IA, IB,
IIA and IIB, respectively. Local recurrence occurred for 1,
6, 5 and 7 tumors among Group IA, IB, IIA and IIB,
respectively. The local recurrence rates of Group IA, IB,
IIA and IIB were 3.6%, 33.3%, 29.4% and 63.6%, respec-
tively. The estimated one-year local recurrence rates were
0%, 14.1%, 41.2% and 63.2% for Group IA, IB, IIA and
IIB, respectively. For Group IA, the estimated 2-, and 3-
year local recurrence rates were 11.1%, and 11.1%,
respectively (Figs. 1, 2). For Group IB, the estimated 2-
year local recurrence rate was 36.2%. The difference
between Group IA and all the other three groups was
statistically significant (p = 0.000). The comparison of
tumor characteristics and follow-up period between Group
IA and the other three Groups altogether is presented in
Table 3. Tumor characteristics were similar among the
groups (Table 3). 
The difference between Group IA and IB and between
Group IB and IIB was also statistically significant (p =
0.001 and 0.003, respectively) (Fig. 3). However, the
difference between Group IB and IIA or between Group
IIA and IIB was not statistically significant (p = 0.600 and
0.146, respectively). The tumor characteristics were also
similar among the four groups (IA, IB, IIA, and IIB). The
period of local tumor recurrence after segmental TACE
ranged from three months to 20 months (median: 10
months). The treatment of the local recurrent tumors
included: RF ablation for six tumors, TACE for 11 tumors
and surgical resection for one tumor. An additional tumor
was conservatively treated because of poor liver function.
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Table 2. Potential Risk Factors for Local Tumor Recurrence of Hepatocellular Carcinoma. Cox Proportional Hazard Model was
Used for the Analysis. Iodized Oil Accumulation Pattern and Tumor Location in Segmental Border Zone were
Significant Adverse Prognostic Factors
Number of Recurred Tumors (n = 19)  Percentage (%) Odds Ratio P-value
Age < 60 years 12/40 30.0 1.37 (0.54 3.48) 0.507
60 years 07/34 20.6
Hepatitis C Negative  17/59 28.8 2.43 (0.56 10.5) 0.237
Positive 02/15 13.3
Modified Child-Pugh class  A  15/52 28.8 1.11 (0.37 3.37) 0.856
B 04/22 18.2
Serum  -fetoprotein 40 ng/mL 11/37 29.7 1.02 (0.41 2.54) 0.975
> 40 ng/mL 08/37 21.6
Serum albumin > 3.5 mg 08/32 25.0 1.55 (0.62 3.89) 0.348
3.5 mg 11/42 26.2
Platelet count  > 150,000 03/8 37.5 1.70 (0.49 5.88) 0.401
150,000 16/66 24.2
Tumor size (cm) 3 cm 15/57 26.3 1.28 (0.42 3.91) 0.660 
3 5 cm 04/17 23.5
Number of nodules Single  10/40 25.0 1.49 (0.58 3.84) 0.412
Multiple 09/34 26.5
Iodized oil Accumulation Homogeneous 07/46 15.2 5.05 (1.92 13.3) 0.001*
Inhomogeneous 12/28 42.9
Segmental border zone No  06/45 13.3 3.58 (1.36 9.43) 0.010*
Yes 13/29 44.8
Subcapsular tumor No 10/31 32.3 1.28 (0.52 3.16) 0.591
Yes 09/43 20.9
Contact with vessel No 16/63 25.4 1.20 (0.35 4.11) 0.777
Yes 03/11 27.3
Note. *: Statistically significant (p-value < 0.05)Prognostic Factors for Local Recurrence of Hepatocellular Carcinoma after Segmental Chemoembolization
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Fig. 1. A 57-year-old male patient with hepatocellular carcinoma. 
A. Pre-embolization arterial phase CT image shows a small high density
lesion within liver segment 5 (white arrow). Portal phase CT imaging showed
washout of the contrast enhancement (not shown). Hepatocellular carcinoma
was diagnosed based on the typical CT findings.
B. Arterial phase pre-embolization hepatic angiogram reveals the
corresponding tumor with hypervascular staining (arrow).
C. Post-embolization hepatic angiogram shows no evidence of residual
tumor staining. Note that the corresponding segmental artery was occluded.
D. One-month follow-up CT imaging, during the arterial phase, shows the
mass with iodized oil accumulation (arrow). There was no evidence of a
residual enhanced portion within or around the tumor.
E. Follow-up CT imaging, during the arterial phase, 29 months after the
segmental transarterial chemoembolization, shows the same mass with
reduction in size (arrow). There was no evidence of local tumor recurrence. 
B A
D C
EEleven of the 17 treated recurrent tumors showed no
evidence of residual viable tumor on the follow-up CT
scan. The estimated 1-year and 3-year overall survival
rates were 92.6% and 48.7%, respectively. At the end of
the study, 16 patients expired; among them, four patients
died with recurrent HCC.
DISCUSSION
The prognostic factors for local recurrence of HCC, after
Park et al.
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Fig. 2. A 61-year-old male patient with hepatocellular carcinoma.
A. Pre-embolization arterial phase CT imaging shows a small high density
lesion located within the segmental border zone between liver segment 6
and 7 (arrow). Portal phase CT imaging showed washout of the contrast
enhancement (not shown). Hepatocellular carcinoma was diagnosed based
on the typical CT findings.
B. Arterial phase pre-embolization hepatic angiogram reveals the
corresponding tumor with hypervascular staining (arrow). The other small
hypervascular mass was confirmed as a hemangioma (arrowheads).
C. Post-embolization hepatic angiogram shows no evidence of residual
tumor staining. Note that the corresponding segmental artery was occluded. 
D. One-month follow-up CT imaging, during the arterial phase, shows the
mass with iodized oil accumulation (arrow). There was no evidence of a
residual enhanced portion within or around the tumor.
E. Follow-up CT imaging, during the portal phase, four months after the
segmental transarterial chemoembolization shows a mass with irregular
margin at the same location, highly suggesting local tumor recurrence
(arrow). Arterial phase imaging showed subtle contrast enhancement of the
lesion (not shown). Hepatic angiogram revealed irregular margined
hypervascular tumor staining, and further transarterial chemoembolization
was performed.
Esegmental TACE, are well known and have been
previously described in the medical literature (3 8).
Recently, tumor location, in segmental border zone, has
been found to be another important prognostic factor (11).
In this study we have demonstrated that the inhomoge-
neous iodized oil accumulation pattern and the tumor
location within the segmental border zone were significant
adverse prognostic factors for local tumor recurrence of
HCC after segmental TACE (11). Therefore, we classified
the tumors into four groups according to the two signifi-
cant prognostic factors identified in this study. Tumor size
was not found to be associated with local tumor
recurrence. This finding is in contrast to prior studies (9,
10), and may have been due to the fact that only tumors
less than or equal to 5 cm were included in this study, and
that relatively strict measures of segmental tumor feeder
occlusion were applied in most cases. 
For Group IA, the recurrence rate was only 3.6%, and
the estimated 3-year local recurrence rate was acceptably
low (11.1%). The local recurrence rate of HCC, after
segmental TACE, reported in prior studies has been
around 30% (9). RF ablation therapy has been previously
used primarily for the treatment of small nodular HCC
tumors (16, 18 22). The local recurrence rate of small
HCCs after RF ablation has been reported to be around
10-20% (16, 18 22). Therefore, the 11.1% estimated 3-
year local recurrence rate in Group IA can be regarded as
acceptably low. The benefit of additional therapy, such as
RF ablation, for these tumors is therefore questionable. 
Our results suggest that if tumors were located within the
liver segment, or a 1-month follow-up CT scan after
segmental TACE revealed compact homogeneous iodized
oil accumulation within the tumors, then just follow-up
with CT imaging would be adequate for local tumor
control. Moreover, in this study, the local recurrence rate
of intermediate sized tumors after segmental TACE was
similar to that of small HCC. However, in many cases it
remains challenging to treat intermediate HCC with RF
ablation (19, 23). RF ablation has been shown to result in
relatively high recurrence rates for tumors in contact with
adjacent hepatic vessels (15, 24 27). Segmental TACE can
be an effective alternative to RF ablation in these
situations, especially for intermediate size tumors or
tumors in contact with adjacent intrahepatic vessels.
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Table 3. Comparison of Tumor Characteristics between the Nodular Tumors Located within Liver Segment with Homogeneous
Iodized Oil Accumulation on the 1-month Follow-up CT Imaging after Segmental Transarterial Chemoembolization
(Group IA) and Other Tumors. Chi-square Test was Used for the Analysis
Group IA Other Groups
Odds Ratio P-value
N = 28 % N = 46 %
HCV
Negative 19 67.9 39 84.8 2.64 (0.85 8.17) 0.086
Positive 09 32.1 07 15.2
Serum AFP
40 ng/mL  13 46.4 24 52.2 1.26 (0.49 3.23) 0.632
> 40 ng/ mL 15 53.6 22 47.8
Serum albumin
> 3.5 mg 14 50.0 18 39.1 1.56 (0.60 4.02) 0.360
3.5 mg 14 50.0 28 60.9
Platelet count
> 150,000 01 03.6 07 15.2 4.85 (0.56 41.7) 0.118
150,000 27 96.4 39 84.8
Tumor size
3 cm 22 78.6 35 76.1 1.54 (0.44 5.43) 0.805
> 3 cm 06 21.4 11 23.9
Average (cm) 2.4 2.4
Subcapsular tumor
No 15 53.6 16 34.8 2.16 (0.83 5.65) 0.112
Yes 13 46.4 30 65.2
Contact with vessel
No 26 92.9 37 80.4 3.16 (0.63 5.65) 0.145
Yes 02 07.1 09 19.6
Median follow-up periods (M)  19  17 Segmental TACE may therefore provide an effective
option in appropriate patients in addition to the palliative
treatment modality. 
Even when the first segmental TACE did not result in a
satisfactory outcome additional therapy, such as RF
ablation can be performed shortly after the segmental
TACE. In Korea, RF ablation therapy is not usually
covered by medical insurance, and this stepwise approach
may reduce the economic burden on patients. Further
studies are needed to better understand the cost-effective-
ness of these procedures. 
The findings from this study suggest that the probability
of local recurrence, after segmental TACE, can be stratified
according to multiple prognostic factors, especially the
iodized oil accumulation pattern and the tumor location
within the segmental border zone. Significant differences
were observed between Group IA and IB, and also
between Group IB and IIB. However, there was no statisti-
cal difference in local recurrence rates between Group IB
and IIA and between Group IIA and IIB. The absence of
significance in these groups may have been caused by the
small size of the tumors included in these groups. Larger
studies will be needed to clarify the statistical difference
between these groups. 
The limitations of this study were as follows. First, the
segmental anatomy was not determined by CT arterio-
portography. However, the final determination of the
segmental anatomy of the tumor was made by consensus
of two experienced abdominal radiologists who traced the
portal venous tree during the portal phase of the spiral CT
scan. Second, a unified helical CT and angiography
approach may improve the clinical results of segmental
TACE. Third, an enhanced area, on the follow-up CT
imaging, might have been masked by overlying iodized oil
accumulation in the tumor. Fourth, the number of tumors
in each group was relatively small. Finally, no pathological
confirmation was obtained for local recurring tumors. 
In conclusion, nodular small or intermediate HCC
showed different rates of local recurrence, after segmental
TACE, according to the iodized oil accumulation pattern
and tumor location within the segmental border zone.
Nodular small or intermediate tumors located within the
liver segment with homogeneous iodized oil accumulation
had an excellent prognosis with regard to local recurrence
after segmental TACE, making additional therapy for
tumor treatment unnecessary.
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